#LATAM ESMO - Eur. Oncology summit is round the corner Are you already registered? 👉 registration link congresstools.com.ar/esmosummit/

Están todos invitados primer congreso de uroncologia de hospitales de la comunidad UroHIBA @uro.oncohiba maticerini aymar mariano #prostatecancer #bladdercancer #RCC HTA_Hospitalitaliano Hospital Británico Hospital Alemán

No olvides de reservar tu lugar!!! Primer congreso de uroncologia de los grandes hospitales de la comunidad. De la teoría a la práctica por los que más hacen esto!!! #uroncologia ⁦UroHIBA⁩ ⁦Hospital Alemán⁩ ⁦Hospital Británico⁩

Pet PSMA will be the new standard imaging modality in prostate cancer? Or is the new standard !!!

Interesting talk by Ravi A Madan M.D. QoL in prostate cancer

Rodrigo Sanchez Roger Felicitaciones!!

Len + Pemb is better than nivo + Cabo in vRCC??

IA help us in the proper classification of 30% HR prostate cancer patients Andrew Armstrong #ASCO2023

luPARP Is it ok to include all comers patients? What do you think ? #ASCO2023

Erdafitinib improved OS in mUC It’s the first target therapy that was compared with chemo in this pathology #asco2023 #bladdercancer

There are an important gap between the academia suggested treatments and the real world patterns!!! Importance of continue medical education #ASCO2023

The benefit of olaparib in mCRPC is mainly driven for the BRCA+subgroup What do you think?

Argentine team wins ASCO23 soccer cup!!! amazing activity with oncologist from every part of the world !!! Thanks Daniel Castellano Toni Choueiri, MD FabriceAndre

It’s difficult to know what to do with VESPER results for neoadjuvant DDMVAC x6 in UC. While the data encouraging it’s statistically negative. Its therefore hard to see it as practice changing from a purist perspective. It may have been +ve with different designs etc but..#ASCO23

💫Exciting news for bladder cancer patients💫:The EV-302 study met its dual primary endpoints of OS and OFS, compared to chemotherapy. An IDMC determined that OS crossed the pre-specified efficacy boundary at interim analysis. Bladder Cancer Advocacy Network OncoAlert Dana-Farber Lank Center for Genitourinary Oncology.

SAN FRANCISCO GU 2024 Cáncer de Próstata Dr. Federico Cayol

Adjuvant pembro ⬆️ DFS (0.69) but ❌ OS (0.98) in UC, ~10% tox ++. Atezo also had ❌ OS. Nivo had 0.7 DFS but no OS data after ++ years-assuming it’s +ve seems unwise. Without OS we’re over treating. Adjuvant IO in all comers is on shaky ground without more data IMO #GU24

Keynote 564: finally the OS results!!! Adjuvant treatment improve it #Gu24 #kidneycancer

Can you amplify ???? Kidney Cancer KidneyCAN KCCure Dana-Farber Lank Center for Genitourinary Oncology Uromigos UroToday.com Cancer Epidemiology, Biomarkers & Prevention Journal of Clinical Oncology AACR ASCO ESMO - Eur. Oncology Tom Powles Brian Rini, MD Laurence Albiges Wenxin (Vincent) Xu Tian Zhang, MD, MHS Rana McKay, MD, FASCO Stephanie Berg

💫🌟I have long been deeply convinced that knowledge is circular and that it is built between knowledge, paths and professions that each one chooses to follow. On that path, we, but also our disciplinary boundaries, become extensive, precisely to transform with each experience